Recombinant human p53 adenovirus injection (Gendicine)

General Information Specification: 1 × 1012VP per piece

Dilution method: After natural thawing at room temperature, dilute with an appropriate amount of physiological saline

Storage method: Store in a -20 ℃ refrigerator to avoid repeated freezing and thawing. Recombinant human p53 adenovirus injection (Gendice) is a genetically engineered recombinant human p53 gene adenovirus particle (rAd-p53) with infectious activity. It consists of replication defective human adenovirus type 5 and normal p53 tumor suppressor gene. The replication defective adenovirus particle serves as a carrier to introduce the p53 gene into tumor cells. The p53 gene is expressed as p53 protein in tumor cells to exert biological functions such as inhibiting tumor cell growth, causing tumor cell apoptosis, inhibiting tumor tissue angiogenesis, and bystander effect. Born again today? In 2004, it was approved by the State Food and Drug Administration (SFDA) of China (approval number: National Medical Products Administration Approval No. S20040004) for the clinical treatment of nasopharyngeal carcinoma through local intratumoral injection. It is the world's first tumor gene therapy drug to be marketed. Since its approval and GMP certification by the State Food and Drug Administration in April 2004, clinical doctors have treated tens of thousands of patients with malignant tumors, including tumors originating from various tissue sources. More than 100 articles have been published in domestic and foreign biological journals. Summarizing the clinical application results, there are the following advantages in treating malignant tumors:

1) The basic biological mechanism is very clear;

2) Multi pathway and multi-faceted anti-tumor effects;

3) Broad spectrum anti-tumor effect, most malignant tumors have p53 gene mutations;